| News
Tolremo raises additional funding
15.06.2020
The Muttenz-based biotechnology company Tolremo Therapeutics has raised an additional 4.7 million Swiss francs as part of a financing round. The company develops cancer therapies for precision medicine and is now driving forward clinical development.

Having raised an additional 4.7 million Swiss francs, Tolremo Therapeutics has now received a total of 13.7 million Swiss francs from a Series A financing round, as detailed in a press release. In addition to the venture capitalists BioMedPartners AG and Altos Venture AG, existing investors such as the Cantonal Bank of Zurich (ZKB) and Redalpine Venture Partners AG have now decided to get involved.
Tolremo develops cancer therapies for precision medicine with the aim of preventing resistances. The successful financing round should now see the first product candidate for clinical development advanced further. Moreover, the development program of the Basel-based company is also set to be expanded.
Resistance against cancer drugs continues to be a major hurdle in achieving long-term patient benefit, explains Stefanie Flückiger-Mangual, Co-Founder and CEO of Tolremo, in the press release. The additional funding will bring the development of resistance-preventing precision therapies for cancer patients one step closer.
Tolremo will also be strengthening its management team. In this context, Reinhard Ambros, the former Global Head of the Novartis Venture Fund, has been named Chairman of the Board. In addition, Guido Hartmann, former Head of Pharmacology at Therachon AG, will join the company in the role of COO/Head Translational Sciences.
Tolremo Therapeutics was also supported by BaseLaunch, which is the Basel Area-based incubator and accelerator that helps scientists and entrepreneurs launch exceptional biotech companies. BaseLaunch is operationally run and financed by Basel Area Business & Innovation, the investment and innovation promotion agency of the Basel Area.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Opterion Health AG moving to Muttenz
Opterion is moving from the canton of Obwalden to Muttenz in the canton of Basel-Landschaft in order to benefit from...
Read MoreEvolva brings natural sugar blocker to market
The biotech company Evolva is introducing L-arabinose to the market. This product is a natural sugar blocker and can be...
Read MoreHolmusk opens new office in Basel
Holmusk has opened an office in Basel. The company from Singapore develops digital therapies on the basis of data analysis....
Read MoreZifo RnD Solutions coming to Basel
Zifo RnD Solutions, a global provider of IT solutions for research-based organizations, opens its latest subsidiary in Basel. With Zifo...
Read MoreAnnouncing the chosen ventures for the DayOne Accelerator (2020/2021)
The DayOne Accelerator ventures for 2020/21 have been chosen. Over 100 teams applied for the program which will run from...
Read More«We will show the new product at the Olympic Games 2021 in Tokyo»
The new Basel Area Business & Innovation Podcast offers exciting conversations with interesting interview partners. The first guest is surgeon...
Read More